# Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)

> **NCT06580873** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Saskatchewan Health Authority - Regina Area** · enrollment: 40 (estimated)

## Conditions studied

- HIV-1-infection
- Opioid Use Disorder

## Interventions

- **DRUG:** DOVATO

## Key facts

- **NCT ID:** NCT06580873
- **Lead sponsor:** Saskatchewan Health Authority - Regina Area
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-05-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06580873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06580873, "Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06580873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*